Cipla's wholly-owned subsidiary, Inzpera Healthsciences, is merging with Cipla.

This amalgamation aims to unlock synergies, enhance cost efficiency, and boost overall shareholder value through resource consolidation.

As Inzpera is fully owned, no new shares will be issued, ensuring no dilution for existing Cipla shareholders.

The National Company Law Tribunal has approved the scheme.

The combined entity is expected to maintain a positive net worth, with no significant adverse financial impact.

Cipla's unsecured creditors, totaling INR 2,204.85 Cr, are not anticipated to be affected by this strategic move.